| | | March 23, 2022 Welcome to the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks. Keep an eye out for our Premarket Reports moving forward and, as always, we invite you to reply to this email with your feedback, suggestions, or comments. It's Wednesday, March 23rd. Let's get ready to trade! |
The Nasdaq bounced back to gain 2.0% on Tuesday, and the S&P 500 added 1.1%. The Dow advanced 0.7%, and the small-cap Russell 2K climbed 1.1%. Today, futures are showing losses in the premarket. S&P 500 contracts are currently down 0.4%. General Mills [GIS] - Last Close: $62.68 General Mills is up after a strong earnings report.
The consumer foods giant released its fiscal Q3 earnings report this morning, and the numbers were better than expected. General Mills reported adjusted earnings of $0.84 per diluted share in the quarter on revenues of $4.54 billion. The firm's earnings topped the Street's $0.78 EPS forecast, and revenues exactly matched the consensus target of $4.54 billion. General Mills also raised its fiscal year 2022 EPS growth forecast. It now expects EPS growth of 0% to 2% during its fiscal year, after a previously released forecast predicted its full-year EPS would range between a 2% decline and 1% growth. GIS is one of the top S&P 500 performers this morning with a 3.3% gain. 4D Pharma PLC [LBPS] - Last Close: $4.67 4D Pharma is up after announcing positive clinical data. The company announced that its Part B of its signal finding study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA, hit its primary endpoints among the renal cell carcinoma group ahead of enrollment completion. 4D Pharma intends to discuss the next steps with its partners to determine the path forward for MRx0518 and a potentially pivotal study. The firm will continue to recruit patients into an ongoing study of MRx0518. LBPS is showing a 44.4% gain on active premarket trading volume. Rezolute Inc [RZLT] - Last Close: $3.68 Shares of Rezolute are soaring on an upbeat clinical data release. The clinical-stage biopharmaceutical firm announced positive data from Phase 2b RIZE study of RZ358. The study demonstrated that the drug was safe and tolerable in patients with congenital hyperinsulinism, and it also produced "highly significant" improvements in hypoglycemia. The RIZE study results will be presented in an oral presentation at an upcoming medical congress in 2Q 2022, followed by a conference call hosted by the Company to discuss the data. RZLT is one of the most active premarket stocks, and it's up 38.3% Creative Realities [CREX] - Last Close: $0.858 Creative Realities is trending on the heels of a strong quarter. The digital marketing firm's fourth-quarter results showed revenues grew 8.3% YoY to $5.4 million and beat the consensus estimates of $4.99 million. Creative Realities also earned a net income of $0.20 million in fiscal 2021, after the company ended the previous year with a net loss of $16.8 million. During Q4, the company won a significant new theme park customer who will continue to deploy the hardware. CREX expects to add more than 1,300 billable devices, generating monthly recurring subscription revenue to content management software platforms. The company expects 2022 revenues to exceed $43 million. CREX is trading actively with a 35.2% gain. |
| Gainers Hycroft Mining [HYMC] >> +13.0% AMC Entertainment [AMC] >> +6.2% TMC The Metals Corp. [TMC] >> +13.7% Decliners Centogene [CNTG] >> (22.3%) Gan Ltd [GAN] >> (17.1%) FirstMark Horizon Acquisition Corp. [FMAC] >> (16.9%) Cintas [CTAS] ... AM General Mills [GIS] ... AM Winnebago Industries [WGO] ... AM JinkoSolar [JKS] ... AM KB Home [KBH] ... PM HB Fuller [FUL] ... PM EVgo [EVGO] ... AM |
| New home sales [Feb] ... 10a |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and Ill get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer © 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
